UNICREDIT BANK/CALL/GSK PLC/2300/1/18.06.25 Share Price

Warrant

DE000HD5HUU7

Market Closed - BOERSE MUENCHEN 01:16:24 27/06/2024 am IST
0.17 EUR 0.00% Intraday chart for UNICREDIT BANK/CALL/GSK PLC/2300/1/18.06.25
Current month-56.41%
1 month-61.36%
Date Price Change
26/24/26 0.17 0.00%
25/24/25 0.17 -10.53%
24/24/24 0.19 0.00%
21/24/21 0.19 0.00%
20/24/20 0.19 0.00%

Real-time BOERSE MUENCHEN

Last update June 27, 2024 at 01:16 am IST

More quotes

Static data

Product typeWarrants
Buy / SellCALL
Underlying GSK PLC
IssuerLogo Issuer UniCredit UniCredit
WKN HD5HUU
ISINDE000HD5HUU7
Date issued 13/05/2024
Strike 2,300 p
Maturity 18/06/2025 (357 Days)
Parity 1 : 1
Emission price 0.46
Emission volume N/A
Settlement règlement en espèces
Currency EUR

Technical Indicators

Highest since issue 0.47
Lowest since issue 0.17
Delta0.1x
Omega 10.37
Premium44.75x
Gearing105.01x
Moneyness 0.6954
Difference Strike 700.5 p
Difference Strike %+30.46%
Spread 0.14
Spread %56.00%
Theoretical value 0.1750
Implied Volatility 22.44 %
Total Loss Probability 93.59 %
Intrinsic value 0.000000
Present value 0.1750
Break even 2,314.81 €
Theta-0.01x
Vega0.03x
Rho0.02x

Company Profile

GSK plc is a global biopharma company. The Company’s segments include Commercial Operations and Research and Development. It develops cancer medicines for patients, including ovarian cancer, endometrial cancer, and multiple myeloma. Its product areas include vaccines, specialty medicines, and general medicine. It is also focused on addressing the unmet treatment needs of patients with respiratory and inflammatory conditions. Its vaccine portfolio includes over 20 vaccines that help to protect people from a range of diseases and infections, including meningitis, shingles and flu, among others. Its specialty medicines are also engaged in developing medicines for respiratory disease and HIV. Its general medicines include inhaled medicines for asthma and chronic obstructive pulmonary disease, antibiotics, and medicines for skin diseases. It is advancing oligonucleotide therapeutics in chronic hepatitis B and steatotic liver disease as well as other therapeutic areas beyond liver disease.
Sector
-
More about the company

Ratings for GSK plc

Trading Rating
Investor Rating
ESG Refinitiv
B
More Ratings

Consensus: GSK plc

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
22
Last Close Price
16 GBP
Average target price
20.36 GBP
Spread / Average Target
+27.32%
Consensus